Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00

Alcon

Status

Completed

Conditions

Cataract

Treatments

Device: AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL

Study type

Interventional

Funder types

Industry

Identifiers

NCT02529488

ILH297-P002

Details and patient eligibility

About

The purpose of this study is to investigate visual outcomes and assess safety at 12 months (330-420 days) post bilateral implantation of the AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL.

Full description

This study will be conducted in regions where the test article is approved at the time of study start.

Enrollment

167 patients

Sex

All

Ages

22+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of bilateral cataracts with planned cataract removal by phacoemulsification with a clear cornea incision;
Able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures;
Clear intraocular media other than cataract in both eyes;
Other protocol-specified inclusion criteria may apply.

Exclusion criteria

Clinically significant corneal abnormalities including corneal dystrophy, inflammation or edema;
Ocular trauma, corneal transplant, retinal conditions, degenerative eye disorders, or color vision deficiencies;
Glaucoma (uncontrolled or controlled with medication) or ocular hypertension;
Pregnant or lactating;
Expected to require ocular surgical or retinal laser treatment;
Other protocol-specified exclusion criteria may apply.